ZEISS Ventures and M2Care invest in Maculaser to advance temperature-controlled retinal laser therapy
Helsinki, 28 May 2026 ZEISS Ventures has joined Maculaser’s latest funding round, co-led together with M2Care. The investment marks the […]
News
Maculaser news
Maculaser Joins €32M EU-Funded PhotonMed Initiative to Advance Retinal Care with Photonics
We are proud to announce that Maculaser is now part of PhotonMed, a €32 million European Union (Chips Joint Undertaking,
New Clinical Trial Manager joins Maculaser
We are pleased to announce that Aki Vartiainen joins the Maculaser team as Clinical Trial Manager.Aki brings strong expertise to our
New Clinical Trial Manager joins Maculaser Read more ›
Maculaser’s retinal treatment technology exhibited in Media
Finnish new technology focused magazine T&T (Tekniikka ja Talous) reports on Maculaser’s goals and timeline in developing novel treatments for
Maculaser’s retinal treatment technology exhibited in Media Read more ›
New Head of Regulatory Affairs and Quality Assurance joins the team
We are excited to announce that Kirsty Happonen joins the Maculaser team as Head of Regulatory Affairs and Quality Assurance. Kirsty
New Head of Regulatory Affairs and Quality Assurance joins the team Read more ›
Maculaser awarded Deep Tech Accelerator grant funding
Maculaser has been awarded a 400kEUR Deep Tech Accelerator grant from Business Finland. This brings our total private and public funding
Maculaser awarded Deep Tech Accelerator grant funding Read more ›